{
    "nctId": "NCT02749019",
    "briefTitle": "Dual Integrin \u03b1v\u03b23 and GRPR Targeting PET Imaging in Breast Cancer Patients",
    "officialTitle": "68Ga-NOTA-BBN-RGD PET/CT in Breast Cancer Patients",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Standardized uptake value of 68Ga-NOTA-BBN-RGD in breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Neoplasm identified by X-ray, ultrasound or MRI as breast cancer\n* To provide basic information and sign the written informed consent.\n\nExclusion Criteria:\n\n* Consisted of conditions of mental illness;\n* Severe liver or kidney disease with serum creatinine \\> 3.0 mg/dl (270 \u03bc\u039c) or any hepatic enzyme level 5 times or more than normal upper limit;\n* Severe allergy or hypersensitivity to IV radiographic contrast\n* Claustrophobia to accept the PET/CT scanning\n* Pregnancy or breast feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}